| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000044347 |
| Receipt No. | R000050648 |
| Scientific Title | Safety verification test using a overdose of fermented royal jelly containing food that intended for healthy individuals |
| Date of disclosure of the study information | 2021/12/30 |
| Last modified on | 2021/12/02 (Ver. 3) |
| Basic information | ||
| Public title | Safety verification test using a overdose of fermented royal jelly containing food that intended for healthy individuals | |
| Acronym | Safety verification test using a overdose of fermented royal jelly containing food that intended for healthy individuals | |
| Scientific Title | Safety verification test using a overdose of fermented royal jelly containing food that intended for healthy individuals | |
| Scientific Title:Acronym | Safety verification test using a overdose of fermented royal jelly containing food that intended for healthy individuals | |
| Region |
|
|
| Condition | ||
| Condition | Adult | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | We will check about safety while people take test food excessively for 4 weeks. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | We confirm safety by integrating adverse events, physiological examination, hematological examination, blood biochemical examination, and urinalysis (Measuring before and 2, 4week after intake of test food.). |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Self control |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | functional food
Intake:4,545 mg Ingesion:28days |
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Target subjects must satisfy the following selection criteria.
1. Healthy Japanese men and women between the ages of 20 - 45 years old at the time of giving informed consent. 2. A person who, during the screening period, is not using chronic or seasonal drugs or medical equipment, and is not undergoing rehabilitation therapy. 3. A person who has freely given consent and has understood the purpose of the study. 4. BMI:18.5 - 30.0 5. Excessive exercise can prevent a person from participating in the clinical study. 6. A person who can take three meals a day basically and prohibit great intemperance during the clinical study. 7. A person who can conduct contraception by an appropriate way during the clinical study. 8. Participant who understands that clinical visits are mandatory during clinical study period. 9. A person who are considered fit for the enrollment in the clinical study. |
|||
| Key exclusion criteria | The subjects in conflict with any of the following condition are excluded.
1. Have a disorder to absorption, distribution, metabolism, excretion of food, such as digestive tract, liver, kidney, heart and cardiovascular system 2. A person with a history of the surgery considerable in the gastrointestinal tract site, for example, gastrectomy, stomach and intestines suturation, intestinal tract resection and so on. (Excluding polypectomy and appendectomy) 3. A person with a history of cerebrovascular disorder.(Excluding asymptomatic lacunar infarct) 4. Have a medical history of food allergy disease or asthma. 5. A person with hypersensitivity or idiosyncrasy, such as food allergies. 6. Be Suspected alcohol or drug dependence 7. A parson who participated in other clinical trial at resent (past 84 days) 8. A person who has taken the blood sampling 400 mL or 200 mL within 84 days, or platelet apheresis within 14days at the time of starting this trial 11. Have a irregular habit 12. Had participated over the past 3 months, or currently participate in other clinical trials |
|||
| Target sample size | 10 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Yamada Bee Company, Inc. | ||||||
| Division name | Institute for Bee Products & Health Science, R&D department | ||||||
| Zip code | 708-0393 | ||||||
| Address | 194 Ichiba, Kagamino-cho, Tomata-gun, Okayama 708-0393 Japan | ||||||
| TEL | 0868-54-3825 | ||||||
| ay1255@yamada-bee.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Yamada Bee Company, Inc. | ||||||
| Division name | Functional Ingredient research section, Institute for Bee Products & Health Science, R&D department | ||||||
| Zip code | 708-0393 | ||||||
| Address | 194 Ichiba, Kagamino-cho, Tomata-gun, Okayama 708-0393 Japan | ||||||
| TEL | 0868-54-3825 | ||||||
| Homepage URL | |||||||
| wm2176@yamada-bee.com | |||||||
| Sponsor | |
| Institute | Yamada Bee Company, Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Yamada Bee Company, Inc. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Research Center for Immunological Analysis, Inc. |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Yamada Bee Company Ethics Committee |
| Address | 194 Ichiba, Kagamino-cho, Tomata-gun, Okayama 708-0393 Japan |
| Tel | 0868-54-1199 |
| kk2004@yamada-bee.com | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050648 |